Cervical Cancer Clinical Trials (as of February 2024)

ENGOT- cx20/NSGO-CTU/TROP2

Leading group: NSGO-CTU

Clinical Trial Study: MK2870 (TROP2) in Cervical Cancer

Planned number of patients: 612

Participating groups: tbc

Planned start June 2024

 

ENGOT-cx19/GEICO/eVOLVE

Leading group: GINECO

Clinical Trial Study: PARa-aOrtic LymphAdenectomy in LACC

Planned number of patients: 520

Participating groups: Swiss GO, BGOG, GEICO, NCRI UK

 

ENGOT-cx18/GINECO/PAROLA

Leading group: GINECO

Clinical Trial Study: PARa-aOrtic LymphAdenectomy in LACC

Planned number of patients: 520

Participating groups: Swiss GO, BGOG, GEICO, NCRI UK

 

ENGOT-cx17/GINECO/BRAVA

Leading group: GINECO

Clinical Trial Study: Anti-PD-L1 Balstilimab vs Investigator Choice Chemotherapy in Patients with Recurrent Cervical Cancer  

Planned number of patients: 486

Participating groups: A-AGO,AGO, GEICO, MITO, CEEGOG, SAKK, PGOG, CTI, BGOG, TRSGO, HeCOG, NSGO-CTU, MaNGO, NOGGO, ISGO

 

ENGOT-cx16/CEEGOG/CERVANTES

Leading group: CEEGOG

Clinical Trial Study: CERVANTES (CERVical cancer AdjuvaNt Treatment Study)​ - ​An international randomized trial of radical surgery followed by adjuvant  (chemo)radiation versus no further treatment in patients with early-stage, intermediate-risk cervical cancer patients​

Planned number of patients: 514

Participating groups: PGOG, BGOG, AGO

 

ENGOT-cx15/GEICO/102C

Leading group: GEICO

Clinical Trial Study: GOG-3056 EMD Serono 1L Cervical Ph3 chemo/combo  

Planned number of patients: TBA

Participating groups:  AGO, GINECO, MITO

 

ENGOT-cx13/AGO/FERMATA

Leading group: AGO

Clinical Trial Study: FERMATA Trial: An international randomized double-blind clinical trial of BCD-100 plus platinum-based chemotherapy with and without Bevacizumab versus placebo plus platinum-based chemotherapy with and without Bevacizumab as first-line treatment of subjects with advanced cervical cancer

Planned number of patients: 316

Participating groups:  A-AGO, BGOG, CEEGOG, NSGO, PGOG

 

ENGOT-cx12/BGOG-cx12

Leading group: BGOG

Clinical Trial Study: Phase 3, randomized controlled trial of Tisotumab Vedotin vs Investigator’s choice chemotherapy in 2nd or 3rd line recurrent cervical cancer

Planned number of patients: 482

Participating groups:  NSGO, AGO, MITO, GEICO, GINECO, A-AGO, CEEGOG, CTI, NCRI, DGOG, MaNGO, PGOG

 

ENGOT-cx11/MITO/LACC

Leading group: MITO

Clinical Trial Study: A randomized, phase 3, double-blind study of chemoradiotherapy with or without pembrolizumab for the treatment of high-risk, locally advanced cervical cancer

Planned number of patients: 980

Participating groups: MaNGO, BGOG, CTI, GINECO, HeCOG, CEEGOG, GEICO, ISGO, NCRI, NOGGO, NSGO, A-AGO, MITO, TRSGO, GOG

 

ENGOT-cx4/GINECO/SENTICOL

Leading group: GINECO

Clinical Trial Study: International prospective validation trial of sentinel node biopsy in cervical cancer

Planned number of patients: 950

Participating groups: AGO, MaNGO, NSGO, DGOG, CEEGOG, GCIG, Gotic, KoIGO Trg, CHRU

Next ENGOT meeting

April 11-12, 2024

Milan, Italy

 

You May Also Like

GCA6

GCA WORKSHOPS

Watch the Webcasts 

 

Read More

background

CLINICAL TRIALS

Latest Published Research

 

Read More

patient2

FOR PATIENTS

Key Insights

 

Read More

ESGO2023_380x206

ESGO 2023 Congress

September 28 - October 1, 2023
Istanbul, Türkiye

Read More